Building adVANTage

Roivant Sciences GmbH aims to use the largest-ever equity financing into a private biotech to accelerate the addition of new programs to its family of companies and expand into enabling technologies that can improve the quality and efficiency of drug development.

On Aug. 9, Roivant raised $1.1 billion in an equity financing led by SoftBank Vision Fund. Existing investor Dexcel Pharma also participated. ...